Dealbreaker on MSN
Neurocrine’s $2.9B Soleno buyout brings what could become its next blockbuster drug
Soleno Therapeutics brings Neurocrine Biosciences Vykat XR, a drug commercialized for treating the rare genetic disease ...
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical ...
July 16 (Reuters) - GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San ...
or on the link below. Pharmacotherapy involving hormones and hormone-derived molecules has various potential treatment targets. This includes addressing (partial) hormonal deficiencies, pursuing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results